Unlocking the potential of TNF: From biologic agents to small-molecule inhibitors
Authors:
- 18 March 2026
- journal article
- review article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 310, 118780
Abstract
No abstract availableKeywords
This publication has 155 references indexed in Scilit:
- Biopharmaceutical Switching in Psoriasis TreatmentJAMA Dermatology, 2025
- First‐in‐Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy ParticipantsClinical Pharmacology & Therapeutics, 2025
- Pathophysiology, Clinical Presentation, and Treatment of PsoriasisJAMA, 2020
- Transmembrane TNF‐α is sufficient for articular inflammation and hypernociception in a mouse model of goutEuropean Journal of Immunology, 2015
- Rationally Designed Less Toxic SPD‐304 Analogs and Preliminary Evaluation of Their TNF Inhibitory EffectsArchiv der Pharmazie, 2014
- A Metal‐Based Inhibitor of Tumor Necrosis Factor‐αAngewandte Chemie International Edition, 2012
- Structure‐Based Repurposing of FDA‐Approved Drugs as TNF‐α InhibitorsChemMedChem, 2011
- Structure‐Based Discovery of Natural‐Product‐like TNF‐α InhibitorsAngewandte Chemie International Edition, 2010
- A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti–tumor necrosis factor monoclonal antibody in murine collagen‐induced arthritisArthritis & Rheumatism, 2007
- From Protein Domains to Drug Candidates—Natural Products as Guiding Principles in the Design and Synthesis of Compound LibrariesAngewandte Chemie International Edition, 2002